Romosozumab
Sign in to saveRomosozumab, sold under the brand name Evenity ( or with the pin-pen merger, ), is a medication used to treat osteoporosis. It has been found to decrease the risk of fractures of the spine.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 464383486
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- zu/o
- Drug.target
- Sclerostin
- Drug.tradename
- Evenity
- Drug.MedlinePlus
- a619026
- Drug.DailyMedID
- Romosozumab
- Drug.pregnancy_AU
- B3
- Drug.ATC_prefix
- M05
- Drug.ATC_suffix
- BX06
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
~3 min read
Encyclopedic overview
4 sectionsContents
- Medical uses
- Side effects
- History
- References
Romosozumab, sold under the brand name Evenity ( or with the pin-pen merger, ), is a medication used to treat osteoporosis. It has been found to decrease the risk of fractures of the spine.
Common side effects include headache, joint pain, and injection site reactions including pain. It may increase the risk of heart attacks, strokes, and deaths from cardiovascular disease. It is a humanized monoclonal antibody that targets sclerostin. Research shows the drug increases bone formation and decreases bone resorption in postmenopausal women with low bone density. Romosozumab was approved for medical use in Japan, the United States and the European Union in 2019.
Excerpted from Wikipedia’s “Romosozumab” article, available under the CC BY-SA 4.0 licence.